Adaptive immunity to Lymphocytic choriomeningitis virus: New insights into antigenic determinants

Future Virology

Volumn 2, Issue 5, 2007, Pages 495-508

  Botten, Jason W ^a   Kotturi, Maya F ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Acute infection; Antibody; Arenavirus; Cell mediated; Epitope; Humoral; Immune response; Lymphocytic choriomeningitis virus; Neutralizing; Protection; Vaccine; Viral persistence

Indexed keywords

CELL PROTEIN; EPITOPE; INTERLEUKIN 10; PROGRAMMED CELL DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ANTIGENICITY; ASEPTIC MENINGITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHORIORETINITIS; DISEASE SEVERITY; FATALITY; HUMAN; HUMORAL IMMUNITY; HYDROCEPHALUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; INFECTION; INTRAUTERINE INFECTION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICROCEPHALY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS MENINGITIS;

ARENAVIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MURINAE; MUS;

EID: 34648827083     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.5.495     Document Type: Review

References (112)

1. Buchmeier MJ, Bowen MD, Peters CJ: Arenaviridae: the viruses and their replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM et al. (Eds). Lippincott Williams & Wilkins: Philadelphia, PA, USA 1635-1668 (2001).
2. Buchmeler MJ, Zajac AJ: Lymphocytic choriomenigitis virus. In: Persistent Virus Infections. Ahmed R, Chen I (Eds). John Wiley & Sons Ltd, UK (2001).
3. Peters CJ: Lymphocytic choriomeningitis virus - an old enemy up to new tricks. N. Engl. J. Med. 354, 2208-2211 (2006).
4. Adair CV, Gauld RL, Smadel JE: Aesptic meningitis, a disease of diverse etiology: clinical and etiologic studies on 854 cases. Ann. Int. Med. 39, 675-704 (1953).
5. Meyer HM, Johnson RT, Crawford EP, Dascomb HE, Rogers NG: Central nervous system syndromes of 'viral' etiology. Am. J. Med. 29, 334-347 (1960).
6. Barton LL, Hyndman NJ: Lymphocytic choriomeningitis virus: reemerging central nervous system pathogen. Pediatrics 105, E35 (2000).
7. Bechtel RT, Haught KA, Mets MB: Lymphocytic choriomeningitis virus: a new addition to the TORCH evaluation. Arch. Ophthalmol. 115, 680-681 (1997).
8. Larsen PD, Chartrand SA, Tomashek KM, Hauser LG, Ksiazek TG: Hydrocephalus complicating Lymphorytic choriomeningitis virus infection. Pediatr. Infect. Dis. J. 12, 528-531 (1993).
9. Barton LL, Budd SC, Morfitt WS et al.: Congenital Lymphocytic choriomeningitis virus infection in twins. Pediatr. Infect. Dis. J. 12, 942-946 (1993).
10. Mets MB, Barton LL, Khan AS, Ksiazek TG: Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis. Am. J. Ophthalmol. 130, 209 (2000).
11. Barton LL, Mets MB, Beauchamp CL: Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am. J. Obstet. Gynecol. 187. 1715-1716 (2002).
12. Fischer SA. Graham MB, Kuehnert MJ et al.: Transmission of Lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 354, 2235-2249 (2006).
13. Gessner A. Lother H: Homologous interference of Lymphocytic choriomeningitis virus involves a ribavirin-susceptible block in virus replication. J. Virol. 63, 1827-1832 (1989).
14. Ruiz-Jarabc, CM, Ly C, Domingo E, de la Torre JC: Lethal mutagenesis of the prototypic arenavirus Lymphocytic chariomeningitis virus (LCMV). Virology 308. 37-47 (2003).
15. Buchmeier MJ. de la Torre JC, Peters CJ, Arenaviridae: the viruses and their replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM et al. (Eds). Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA, USA 1791-1827 (2007).
16. Lehmann-Grube F: Lymphocytic choriomeningitis virus. In: Virology Monographs. Springer Verlag, NY, USA (1971).
17. Childs JC, Peters CJ: Ecology and epidemiology of arenaviruses and their hosts. In: The Arenaviridae. Salvato MS (Ed.). Plenum Press, NY, USA, 331-373 (1993).
18. Parker JC, Igel HJ, Reynolds RK, Lewis AM Jr. Rowe WP: Lymphocytic choriomeningitis virus infection in fetal, newborn, and young adult Syrian hamsters (Mesocricetus auratus). Infect. Immun. 13, 967-981 (1976).
19. Hotchin J, Sikora E, Kinch W, Hinman A, Woodall J: Lymphocytic choriomeningitis in a hamster colony causes infection of hospital personnel. Science 185, 1173-1174 (1974).
20. Hinman AR, Fraser DW, Douglas RG et al.: Outbreak of Lymphocytic choriomeningitis virus infections in medical center personnel. Am. J. Epidemiol. 101, 103-110 (1975).
21. Hirsch MS, Moellering RC Jr, Pope HG, Poskanzer DC: Lymphocytic-choriomeningitis-virus infection traced to a pet hamster. N. Engl. J. Med. 291, 610-612 (1974).
22. Childs JE, Glass GE, Korch GW Ksiazek TG, Leduc JW: Lymphocytic choriomeningitis virus infection and house mouse (Mus musculus) distribution in urban Baltimore. Am. J. Trop. Med. Hyg. 47, 27-34 (1992).
23. Cole GA, Nathanson N, Prendergast RA: Requirement for theta-bearing cells in Lymphocytic choriomeningitis virus-induced central nervous system disease. Nature 238, 335-337 (1972).
24. Borrow P, Oldstone MBA: Lymphocytic choriomeningitis virus. In: Viral Pathogenesis. Nathanson N (Ed.). Lippincott-Raven Publishers, Philadelphia, PA, USA 593-627 (1996).
25. Kagi D, Ledermann B, Burki K et al.: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369, 31-37 (1994).
26. Walsh CM, Matloubian M, Liu CC et al.: Immune function in mice lacking the perforin gene. Proc. Natl Acad. Sci. USA 91, 10854-10858 (1994).
27. Klavinskis LS, Whitton JL, Oldstone MB: Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J. Virol. 63, 4311-4316 (1989).
28. Schutz M, Zinkernagel RM, Hengartner H: Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl Acad. Sci. USA 88, 991-993 (1991).
29. Borten J, Whitton JL, Barrowman P et al.: HLA-A2-restricted protection against lethal lymphocytic choriomeningitis. J. Virol. 81, 2307-2317 (2007).
30. + T-cell response to Lymphocytic choriomeningitis virus involves the L antigen: uncovering new tricks for an Old Virus. J. Virol. 81, 4928-4940 (2007).
31. Botten J, Alexander J, Pasquetto V et al.: Identification of protective Laza virus epitopes that are restricted by HLA-A2. J. Virol.. 80, 8351-8361 (2006).
32. Rodriguez-Carreno MP, Nelson MS, Botten J, Smith-Nixon K, Buchmeier MJ, Whitton JL: Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 335, 87-98 (2005).
33. Bartholdy C, Christensen JP, Wodarz D, Thomsen AR: Persistent virus infection despite chronic cytotoxic T-lymphocyte activation in gamma interferon-deficient mice infected with Lymphocytic choriomeningitis virus. J. Virol. 74, 10304-10311 (2000).
34. Cerny A, Sutter S, Bazin H, Hengartner H, Zinkernagel RM: Clearance of Lymphocytic choriomeningitis virus in antibody- and B-cell-deprived mice. J Virol. 62, 1803-1807 (1988).
35. Southern PJ: Arenaviridae: The viruses and their replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM et al. (Eds). Lippencott-Raven, Philadelphia, PA, USA 1505-1519 (1996).
36. Bruns M. Cihak J, Muller G, Lehmann-Grube F: Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization. Virology 130, 247-251 (1983).
37. Koup RA, Safrit JT, Cao Y et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
38. Shata MT, Anthony DD, Carlson NL et al.: Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J. Viral Hepat. 9, 400-410 (2002).
39. Buchmeier MJ, Welsh RM, Dutko FJ, Oldstone MB: The virology and immmunobiology of Lymphocytic choriomeningitis virus infection. Adv. Immunol. 30, 275-331 (1980).
40. Clegg JCS: Current progress towards vaccines for arenavirus-caused diseases. Vaccine 10, 89-95 (1992).
41. Fisher-Hoch SP, McCormick JB: Towards a human Lassa fever vaccine. Rev. Med. Virol. 11, 331-341 (2001).
42. McCormick JB, Fisher-Hoch SP: Lassa fever. Curr. Top. Microbiol. Immunol. 262, 75-109 (2002).
43. Recher M, Hunziker L, Ciurea A, Harris N, Lang KS: Public, private and non-specific antibodies induced by non-cytopathic viral infections. Curr. Opin. Microbiol. 7, 426-433 (2004).
44. Hangartner L, Zinkernagel RM, Hengartner H: Antiviral antibody responses: the two extremes of a wide spectrum. Nat. Rev. Immunol. 6, 231-243 (2006).
45. Baldridge JR, McGraw TS, Paoletti A, Buchmeier MJ: Antibody prevents the establishment of persistent Arenavirus infection in synergy with endogenous T cells. J. Virol. 71, 755-758 (1997).
46. Brundler MA, Aichele P, Bachmann M, Kitamura D, Rajewsky K, Zinkernagel RM: Immunity to viruses in B cell-deficient mice: influence of antibodies on virus persistence and on T cell memory. Eur. J. Immunol. 26, 2257-2262 (1996).
47. Bachmann MF, Hunziker L, Zinkernagel RM, Storni T, Kopf M: Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key. Eur. J. Immunol. 34, 317-326 (2004).
48. Seiler P, Brundler MA, Zimmermann C et al.: Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J. Exp. Med. 187, 649-654 (1998).
49. Wright KE, Buchmeier MJ: Antiviral antibodies attenuate T-cell-mediated immunopathology following acute Lymphocytic choriomeningitis virus infection. J. Virol. 65, 3001-3006 (1991).
50. Althage A, Odermatt B, Moskophidis D et al.: Immunosuppression by Lymphocytic choriomeningitis virus infection: competent effector T and B cells but impaired antigen presentation. Eur. J. Immunol. 22, 1803-1812 (1992).
51. Odermatt B, Eppler M, Leist TP, Hengartner H, Zinkernagel RM: Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. Proc. Natl Acad. Sci. USA 88, 8252-8256 (1991).
52. Hunziker L, Recher M, Macpherson AJ et al.: Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat. Immunol. 4, 343-349 (2003).
53. Jellison ER, Guay HM, Szomolanyi-Tsuda E, Welsh RM: Dynamics and magnitude of virus-induced polyclonal B cell activation mediated by BCR-independent presentation of viral antigen. Eur. J. Immunol. 37, 119-128 (2007).
54. Recher M, Lang KS, Hunziker L et al.: Deliberate removal of T cell help improves virus-neutralizing antibody production. Nat. Immunol. 5, 934-942 (2004).
55. Pinschewer DD, Perez M, Jeetendra E et al.: Kinetics of protective antibodies are determined by the viral surface antigen. J. Clin. Invest. 114, 988-993 (2004).
56. Pinschewer DD, Perez M, Sanchez AB, de la Torre JC: Recombinant Lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc. Natl Acad. Sci. USA 100, 7895-7900 (2003).
57. + T cells during acute infection with Lymphocytic choriomeningitis virus. J. Immunol. 161, 3215-3218 (1998).
58. Christensen JE, Christensen JP, Kristensen NN, Hansen NJ, Stryhn A, Thomsen AR: Role of CD28 co-stimulation in generation and maintenance of virus-specific T cells. Int. Immunol. 14, 701-711 (2002).
59. Whitmire JK, Flavell RA, Grewal IS, Larsen CP, Pearson TC, Ahmed R: CD40-CD40 ligand costimulation is required for generating antiviral CD4 T cell responses but is dispensable for CD8 T cell responses. J. Immunol. 163, 3194-3201 (1999).
60. Havenar-Daughton C, Kolumam GA, Murali-Krishna K: Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J. Immunol. 176, 3315-3319 (2006).
61. Fuller MJ, Hildeman DA, Sabbaj S et al.: Cutting edge: emergence of CD127 high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help. J. Immunol. 174, 5926-5930 (2005).
62. + memory T cells are IL-15 dependent. J. Exp. Med. 204, 951-961 (2007).
63. Whitmire JK, Asano MS, Murali-Krishna K, Suresh M, Ahmed R: Long-term CD4 Th1 and Th2 memory following acute Lymphocytic choriomeningitis virus infection. J. Virol. 72, 8281-8288 (1998).
64. Jellison ER, Kim SK, Welsh RM: Cutting edge: MHC class II-restricted killing in vivo during viral infection. J. Immunol. 174, 614-618 (2005).
65. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056-8063 (1994).
66. + T lymphocytes. Nature 421, 852-856 (2003).
67. Shedlock DJ, Shen H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337-339 (2003).
68. + T cells after acute infection. Nat. Immunol. 5, 927-923 (2004).
69. Zajac AJ. Blattman JN, Murali-Krishna K et al.: Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
70. + T cells upon acute versus persistent viral infection. Immunity 9, 449-457 (1998).
71. + T cell responses directed against a broad range of epitopes. J. Immunol. 179, 1058-1067 (2007).
72. Brooks DG, Teyton L, Oldstone MB, McGavern DB: Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J. Virol. 79, 10514-10527 (2005).
73. + T-cell clones. Virology 321, 134-143 (2004).
74. + T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J. Virol. 74, 2186-2192 (2000).
75. + T lymphocytes because of disruption of the beta 2-microglobulin gene. J. Virol. 67, 332-339 (1993).
76. Wille A, Gessner A, Lother H, Lehmann-Grube F: Mechanism of recovery from acute virus infection. VIII. Treatment of Lymphocytic choriomeningitis virus-infected mice with anti-interferon-gamma monoclonal antibody blocks generation of virus-specific cytotoxic T lymphocytes and virus elimination. Eur. J. Immunol. 19, 1283-1288 (1989).
77. Oldstone MB: Biology and pathogenesis of Lymphocytic choriomeningitis virus infection. Curr. Top. Microbiol. Immunol. 263, 83-117 (2002).
78. Masopust D, Murali-Krishna K, Ahmed R: Quantitating the magnitude of the Lymphocytic choriomeningitis virus-specific CD8 T-cell response: it is even bigger than we thought. J. Virol. 81, 2002-2011 (2007).
79. + T cells during viral infection. J. Immunol. 170, 4745-4751 (2003).
80. Wherry EJ, Ahmed R: Memory CD8 T-cell differentiation during viral infection. J. Virol. 78, 5535-5345 (2004).
81. +-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol. 77, 5226-5240 (2003).
82. +)-cell responses to vaccinia virus. Nat. Biotechnol. 24, 817-819 (2006).
83. Chen W, Anton LC, Bennink JR, Yewdell JW: Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12, 83-93 (2000).
84. Kedl RM, Rees WA, Hildeman DA et al.: T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med. 192, 1105-1113 (2000).
85. Selin LK, Nahill SR, Welsh RM: Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses. J. Exp. Med. 179, 1933-1943 (1994).
86. Kim SK, Cornberg M, Wang XZ, Chen HD, Selin LK, Welsh RM: Private specificities of CD8 T cell responses control patterns of heterologous immunity. J. Exp. Med. 201, 523-533 (2005).
87. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK: T cell Immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat. Immunol. 3, 627-634 (2002).
88. Selin LK, Varga SM, Wong IC, Welsh RM: Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J. Exp. Med. 188, 1705-1715 (1998).
89. Cornberg M, Chen AT, Wilkinson LA et al.: Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J. Clin. Invest. 116, 1443-1456 (2006).
90. Keir ME, Liang SC, Guleria I et al.: Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203, 883-895 (2006).
91. Barber DL, Wherry EJ, Masopust D et al.: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
92. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R: Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol.. 77, 4911-4927 (2003).
93. Florentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147, 3815-3822 (1991).
94. Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin 10. J. Exp. Med. 174, 1549-1555 (1991).
95. Blackburn SD, Wherry EJ: IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 15, 143-146 (2007).
96. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB: Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12, 1301-1309 (2006).
97. Ejrnaes M, Filippi CM, Martinic MM et al.: Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 203, 2461-2472 (2006).
98. Rigopoulou EI, Abbott WG, Haigh P, Naoumov NV: Blocking of interleukin-10 receptor - a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clin. Immunol. 117, 57-64 (2005).
99. + T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202 (2006).
100. Urbani S, Amadet B, Tola D et al.: PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 80, 11398-11403 (2006).
101. + T cell activation. Eur. J. Immunol. 36, 2472-2482 (2006).
102. Oxenius A, Bachmann MF, Mathis D, Benoist C, Zinkernagel RM, Hengartner H: Functional in vivo MHC class II loading by endogenously synthesized glycoprotein during viral infection. J. Immunol. 158, 5717-5726 (1997).
103. + T cell core epitope by both MHC class I and MHC class II. Vrology 363, 113-123 (2007).
104. Kamperschroer C, Quinn DG: Quantification of epitope-specific MHC class-II-restricted T cells following Lymphocytic choriomeningitis virus infection. Cell. Immunol. 193, 134-146 (1999).
105. Klavinskis LS, Whitton JL, Joly E, Oldstone MB: Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology 178, 393-400 (1990).
106. van der Most RG, Murali-Krishna K, Whitton JL et al.: Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in Lymphocytic choriomeningitis virus-infected mice. Virology 240, 158-167 (1998).
107. van der Most RG, Murali-Krishna K, Lanier JG et al.: Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology 315, 93-102 (2003).
108. van der Most RG, Sette A, Oseroff C et al.: Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic Lymphocytic choriomeningitis virus infection. J. Immunol. 157, 5543-5554 (1996).
109. Battegay M, Oehen S, Schulz M, Hengartner H, Zinkernagel RM: Vaccination with a synthetic peptide modulates Lymphocytic choriomeningitis virus-mediated immunopathology. J. Virol. 66, 1199-1201 (1992).
110. +) T-cell populations with differing cytolytic activities. J. Virol. 75, 7399-7409 (2001).
111. k restricted CTL clones recognize internal viral gene products and cause CNS disease. J. Neuroimmunol. 41, 15-20 (1992).
112. Bui HH, Botten J, Fusseder N et al.: Protein sequence database for pathogenic arenaviruses. Immunome Res. 3, 1 (2007).